

# Thomas E MÃ¼rdter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6600298/publications.pdf>

Version: 2024-02-01

69  
papers

2,997  
citations

186265

28  
h-index

168389

53  
g-index

70  
all docs

70  
docs citations

70  
times ranked

4054  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models. <i>British Journal of Pharmacology</i> , 2022, 179, 2906-2924.	5.4	14
2	Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches. <i>Analytica Chimica Acta</i> , 2022, 1202, 339661.	5.4	7
3	Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 799-809.	4.1	7
4	(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 511.	2.5	3
5	Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine. <i>Talanta</i> , 2021, 221, 121658.	5.5	6
6	Raman Imaging and Fluorescence Lifetime Imaging Microscopy for Diagnosis of Cancer State and Metabolic Monitoring. <i>Cancers</i> , 2021, 13, 5682.	3.7	11
7	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2020, 26, 6523-6534.	7.0	16
8	Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. <i>Analytica Chimica Acta</i> , 2020, 1134, 125-135.	5.4	15
9	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 661-670.	4.7	17
10	Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. <i>Cell Death and Differentiation</i> , 2020, 27, 3037-3052.	11.2	17
11	Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same. <i>Journal of Clinical Oncology</i> , 2019, 37, 1981-1982.	1.6	16
12	Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites. <i>Frontiers in Pharmacology</i> , 2019, 10, 530.	3.5	21
13	The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. <i>Archives of Toxicology</i> , 2018, 92, 1099-1112.	4.2	18
14	Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem. <i>Anticancer Research</i> , 2018, 38, 1585-1593.	1.1	4
15	Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. <i>Frontiers in Pharmacology</i> , 2017, 8, 582.	3.5	52
16	Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest. <i>Cancer Research</i> , 2016, 76, 2868-2875.	0.9	63
17	Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. <i>Oncotarget</i> , 2016, 7, 53526-53539.	1.8	9
18	Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 7497-7502.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na <sup>+</sup> -taurocholate cotransporting polypeptide inhibitor. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 6815-6825.	3.7	35
20	Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy. <i>Annals of Surgical Oncology</i> , 2014, 21, 553-559.	1.5	287
21	Simulation with cells <i>in vitro</i> of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. <i>British Journal of Pharmacology</i> , 2014, 171, 5624-5635.	5.4	29
22	A new [ <sup>2</sup> H] <sub>2</sub> -labelled trichloroimidate glucuronic ester for the synthesis of deuterated drug conjugates. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 699-703.	1.0	3
23	The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1906-1913.	3.3	8
24	Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. <i>Human Molecular Genetics</i> , 2012, 21, 1145-1154.	2.9	37
25	Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin. <i>Cancer Research</i> , 2012, 72, 5824-5832.	0.9	25
26	Simultaneous quantitative analysis of letrozole, its carbinol metabolite, and carbinol glucuronide in human plasma by LC-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 301-308.	3.7	24
27	Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 708-717.	4.7	241
28	Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense 2'-O-methyl-RNA. <i>International Journal of Pharmaceutics</i> , 2011, 419, 33-42.	5.2	28
29	Quantification of clomiphene metabolite isomers in human plasma by rapid-resolution liquid chromatography-electrospray ionization-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 3429-3441.	3.7	14
30	Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1-3.	1.9	4
31	Nanoparticle mediated delivery of 2'-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. <i>Lung Cancer</i> , 2010, 68, 346-354.	2.0	29
32	Pharmacogenomics of Tamoxifen Therapy. <i>Clinical Chemistry</i> , 2009, 55, 1770-1782.	3.2	142
33	A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1017-1024.	3.3	42
34	Efficient Telomerase Inhibition in Human Non-small Cell Lung Cancer Cells by Liposomal Delivery of 2'-O-Methyl-RNA. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1765-1774.	3.3	13
35	Fate of the Antibiotic Sulfamethoxazole and Its Two Major Human Metabolites in a Water Sediment Test. <i>Environmental Science &amp; Technology</i> , 2009, 43, 3135-3141.	10.0	170
36	Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. <i>BMC Cancer</i> , 2008, 8, 364.	2.6	58

#	ARTICLE	IF	CITATIONS
37	Increased Absorption of Digoxin from the Human Jejunum Due to Inhibition of Intestinal Transporter-Mediated Efflux. <i>Clinical Pharmacokinetics</i> , 2007, 46, 777-785.	3.5	64
38	Role of P-Glycoprotein Inhibition for Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2007, 46, 1039-1049.	3.5	101
39	Synthesis of [2H3]-labelled sulfamethoxazole and its main urinary metabolites. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2007, 50, 656-659.	1.0	5
40	Unchanged serum levels of advanced glycation endproducts in patients with liver disease. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 375, 401-406.	3.0	10
41	TGF $\beta$ 2 and T $\beta$ RII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2007, 107, 15-24.	2.5	21
42	Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. <i>Anticancer Research</i> , 2007, 27, 2131-9.	1.1	31
43	Stereoselective Quantification of Methadone and a d6-labeled Isotopomer Using High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass-Spectrometry: Application to a Pharmacokinetic Study in a Methadone Maintained Subject. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 559-567.	2.0	15
44	Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. <i>BMC Cancer</i> , 2006, 6, 86.	2.6	89
45	Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. <i>Anti-Cancer Drugs</i> , 2005, 16, 337-344.	1.4	23
46	Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. <i>Laboratory Investigation</i> , 2005, 85, 1565-1569.	3.7	26
47	Synthesis of [2H]-labelled phase-I-metabolites using 1-[2H]-pyridinium hydrochloride. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2005, 48, 457-461.	1.0	3
48	Induction of Metallothionein in Proximal Tubular Cells by Zinc and Its Potential as an Endogenous Antioxidant. <i>Kidney and Blood Pressure Research</i> , 2005, 28, 127-133.	2.0	28
49	Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. <i>Respiratory Research</i> , 2005, 6, 21.	3.6	32
50	Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 189-197.	2.5	236
51	Impact of mistletoe lectin binding in breast cancer. <i>Anticancer Research</i> , 2004, 24, 1187-92.	1.1	11
52	P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 223-231.	4.7	139
53	Population pharmacokinetics of oral busulfan in children. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 209-216.	2.3	43
54	Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 791, 371-380.	2.3	18

#	ARTICLE	IF	CITATIONS
55	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 105-111.	2.4	21
56	Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib. <i>Clinical Pharmacokinetics</i> , 2003, 42, 283-292.	3.5	78
57	Dose Optimization of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumor pH Promotes Prodrug Activation by $\beta$ -Glucuronidase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 223-228.	2.5	51
58	Expression of active human $\beta$ -glucuronidase in Sf9 cells infected with recombinant baculovirus. <i>Life Sciences</i> , 2002, 71, 1547-1557.	4.3	5
59	Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]-dextrorphan- $\beta$ -glucuronide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 1153-1158.	1.0	7
60	Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 768, 255-260.	2.3	32
61	The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 157-167.	2.4	118
62	Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: Consequences for enzyme expression and busulfan conjugation*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 479-487.	4.7	73
63	Microsomal Epoxide Hydrolase Expression as a Predictor of Tamoxifen Response in Primary Breast Cancer: A Retrospective Exploratory Study With Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2001, 19, 3-9.	1.6	22
64	P-glycoprotein-mediated transport of digitoxin, $\beta$ -methylidigoxin and $\beta$ -acetyldigoxin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001, 363, 337-343.	3.0	43
65	Syntheses of 2H-labelled dihydropyrimidinediones and their metabolites. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, 7-11.	1.0	5
66	Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. <i>The Histochemical Journal</i> , 2001, 33, 329-336.	0.6	47
67	Expression and function of $\beta$ -glucuronidase in pancreatic cancer: potential role in drug targeting. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2000, 362, 110-115.	3.0	73
68	Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: Is there any prognostic relevance?. <i>Acta Histochemica</i> , 1999, 101, 239-253.	1.8	11
69	Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue. <i>Biomedical Applications</i> , 1998, 709, 289-295.	1.7	15